

# Welcome to Investors Newsletter #9

Bonjour à tous,

It is my pleasure to provide you with an update on DeepLife's progress and achievements for the third quarter of 2023. We appreciate your continued support and trust in our vision, and we are very excited to share some of our latest developments.



## Market Overview :

As usual Q3 is always the time for DeepLife to shine a light on our products and technology at [BiotechX Europe](#). And this year particularly, with 7 of our team members on site and our presentation during one of the most attended speaking sessions on how to use [Digital Twin of cells to discover novel treatments for Lupus](#).

Foundational models for drug discovery were at the heart of all discussions. And DeepLife digital twin of cells, pre-trained with 85 million cells, has never generated so much interest within the Pharma industry.



## New Additions to the Team :

We straightened our team with 3 exceptional new members:

- [Emmanuelle Supper](#), PhD as Chief Commercial Officer brings an extensive and successful experience working with large pharma,
- [Conor Mohan](#), PhD joined alongside Emmanuelle as Scientific Engagement Manager brings a deep understanding of scientific challenges within the industry,
- [Paulo Czarnewski](#), PhD as Sr. Computational Biologist, coming from one of the most prestigious universities in the Omics data realm.



## **Financial Visibility and Funding :**

I'm pleased to report that we are still on track with our financials projections, and our current cash burn rate is well within control. We maintain financial visibility up to December 2024, which provides us with a robust financial foundation to execute our growth plans.

We also engaged strategic collaborations aligned with our commitment to accelerate drug discovery that will be soon announced:

- Identify novel treatments for dementia - A 2,4M€ project coordinated by CNRS,
- Deploy a [data driven approach for pediatric cancer](#) – in collaboration with Inserm,
- Accelerate therapeutic discoveries for Cystinosis (rare disease) – in collaboration with university of Zurich



## **Next Fundraising and outlook for Q4 & beyond :**

To support our ambitious expansion goals, we are actively preparing for our Series A fundraising round. We will provide more details in the coming months as we progress through the fundraising process.

## **DEEPLIFE NEWS WRAPPED-UP**

### **> Highlights**

- Team is complete and 100% operational
- We engaged 3 strategic partnerships including Inserm and University of Zurich

### **> Lowlights**

- Some deals with key Pharma in our pipeline are taking a bit more time to close than expected but we're still on track with our commercial plans

### **> Asks**

- I might contact some of you for intro with VCs

### **> Information**

- After 2 years at Paris Biotech Santé we moved our new offices



to [Future4Care](#) (Paris) right next to Sanofi's desks

Once again, I want to express my gratitude for your continued trust and support. Please feel free to [reach out to me](#) whether you need more information.

Next newsletter will be send out by January 2024.

The DeepLife Team



DeepLife  
Watt-Biopark, 8 Rue Jean Antoine de Baïf, 75013 Paris